A combination of Zenbexus, Darzalex and dexamethasone nearly doubled the rate of deep, MRD-negative responses in relapsed multiple myeloma.
|Articles|November 28, 2022
Upcoming Webinars
Advertisement
Realities of Bladder Cancer in Women
December 8th | 7:00 PM ET
Moving Through Bladder Cancer - How Exercise Impacts Your Treatment and Mental Health
January 11, 2023 at 5:30 pm ET
When Cure Is Not An Option | Managing Difficult Conversations and Treatments at End of Life
January 25th | 5:00 PM ET
Advertisement
Related to this article
She was diagnosed with stage 4 primary mediastinal B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma that starts in the center of the chest, at 29.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
Dr. Maureen McEvoy explains breast cancer surgery options, reconstruction, recovery and how to close gaps in access to care.
For Blood Cancer Awareness Month, Dr. Guenther Koehne shares why immunotherapy is making this a promising time for people with blood cancers.
A cancer survivor reflects on losing her hair during chemotherapy, the emotional impact of hair loss and what growing it back taught her about healing, identity and life.
After a lung cancer diagnosis, one Bronx writer reflects on faith, survivorship and learning that healing isn't a finish line, but a daily journey.
Dr. David DiBardino explains how intratumoral therapy is being studied to deliver treatment directly into tumors and potentially enhance radiation in patients with locally advanced non-small cell lung cancer.
Advertisement
Advertisement
Trending on CURE
1
Could a Genomic Test Spare You Extra Years of Hormone Therapy?
2
We Eat Bagels Before Cancer Treatment. Here’s Why.
3
My Sister and I Share a BRCA2 Mutation. We Didn’t Make the Same Choices
4
Expert Says Blood Cancer Care Is Moving Past Chemotherapy
5